533 related articles for article (PubMed ID: 15514571)
1. Drug-eluting stents: from randomized trials to the real world.
Saia F; Degertekin M; Lemos PA; Serruys PW
Minerva Cardioangiol; 2004 Oct; 52(5):349-63. PubMed ID: 15514571
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
[TBL] [Abstract][Full Text] [Related]
3. Stent thrombosis in randomized clinical trials of drug-eluting stents.
Mauri L; Hsieh WH; Massaro JM; Ho KK; D'Agostino R; Cutlip DE
N Engl J Med; 2007 Mar; 356(10):1020-9. PubMed ID: 17296821
[TBL] [Abstract][Full Text] [Related]
4. Drug-eluting stents.
García-García HM; Vaina S; Tsuchida K; Serruys PW
Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
[TBL] [Abstract][Full Text] [Related]
5. Drug-eluting stent: the emerging technique for the prevention of restenosis.
Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
[TBL] [Abstract][Full Text] [Related]
6. [Drug-eluting stents and other anti-restenosis devices].
Moreno R
Rev Esp Cardiol; 2005 Jul; 58(7):842-62. PubMed ID: 16022816
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials.
Dibra A; Kastrati A; Alfonso F; Seyfarth M; Pérez-Vizcayno MJ; Mehilli J; Schömig A
J Am Coll Cardiol; 2007 Feb; 49(5):616-23. PubMed ID: 17276188
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting stents for in-stent restenosis and acute myocardial infarction: present data from nonrandomized studies.
Schofer J; Bode C; Silber S
Herz; 2004 Mar; 29(2):195-200. PubMed ID: 15057441
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease.
Degertekin M; Regar E; Tanabe K; Lee CH; Serruys PW
Minerva Cardioangiol; 2002 Oct; 50(5):405-18. PubMed ID: 12384623
[TBL] [Abstract][Full Text] [Related]
10. Drug-eluting stents: preventing restenosis.
Slavin L; Chhabra A; Tobis JM
Cardiol Rev; 2007; 15(1):1-12. PubMed ID: 17172878
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting stents and stent thrombosis: a cause for concern?
Wernick MH; Jeremias A; Carrozza JP
Coron Artery Dis; 2006 Dec; 17(8):661-5. PubMed ID: 17119373
[TBL] [Abstract][Full Text] [Related]
13. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials.
Kumbhani DJ; Bavry AA; Kamdar AR; Helton TJ; Bhatt DL
Am Heart J; 2008 Apr; 155(4):640-7. PubMed ID: 18371470
[TBL] [Abstract][Full Text] [Related]
14. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
Silber S
J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
[TBL] [Abstract][Full Text] [Related]
15. Drug-eluting stents.
Chieffo A; Colombo A
Minerva Cardioangiol; 2002 Oct; 50(5):419-29. PubMed ID: 12384624
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
[TBL] [Abstract][Full Text] [Related]
17. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice.
Cosgrave J; Melzi G; Corbett S; Biondi-Zoccai GG; Agostoni P; Babic R; Airoldi F; Chieffo A; Sangiorgi GM; Montorfano M; Michev I; Carlino M; Colombo A
J Am Coll Cardiol; 2007 Jun; 49(24):2320-8. PubMed ID: 17572247
[TBL] [Abstract][Full Text] [Related]
18. Safety of drug-eluting stents in the coronary artery in ST-elevation myocardial infarction at a single high-volume medical center.
Bose R; Gupta G; Grayburn PA; Laible EA; Kang MJ; Choi JW
Am J Cardiol; 2007 Sep; 100(6):949-52. PubMed ID: 17826375
[TBL] [Abstract][Full Text] [Related]
19. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
Buellesfeld L; Grube E
Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
[TBL] [Abstract][Full Text] [Related]
20. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
Ray GM; Nawarskas JJ; Frishman WH
Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
